Distinguished in Retinopathy Pigmentary Mental Retardation

Dr. Christine N. Kay

Ophthalmology
Vitreo Retinal Associates PA
4340 Newberry Rd, Suite 202, 
Gainesville, FL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Distinguished in Retinopathy Pigmentary Mental Retardation
Vitreo Retinal Associates PA
4340 Newberry Rd, Suite 202, 
Gainesville, FL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christine Kay is an Ophthalmologist in Gainesville, Florida. Dr. Kay is rated as a Distinguished provider by MediFind in the treatment of Retinopathy Pigmentary Mental Retardation. Her top areas of expertise are Color Blindness, Retinitis Pigmentosa, Retinopathy Pigmentary Mental Retardation, Late-Onset Retinal Degeneration, and Vitrectomy. Dr. Kay is currently accepting new patients.

Her clinical research consists of co-authoring 47 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 14 articles and participated in 1 clinical trial in the study of Retinopathy Pigmentary Mental Retardation.

Graduate Institution
University Of Florida College Of Medicine
Specialties
Ophthalmology
Licenses
Ophthalmology in FL
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
AvMed
  • HMO
  • POS
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Florida Blue
  • EPO
  • PPO
Health Options
  • HMO
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Sunshine Health
  • EPO
  • HMO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

VITREO RETINAL ASSOCIATES PA
4340 Newberry Rd, Suite 202, Gainesville, FL 32607

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
Enrollment Status: Recruiting
Publish Date: September 15, 2025
Intervention Type: Biological
Study Drugs: 4D-150, Aflibercept
Study Phase: Phase 1/Phase 2
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
A Phase 2 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Long Term Safety, Tolerability, Pharmacokinetics and Effects of ALK-001 on the Progression of Stargardt Disease
Enrollment Status: Enrolling_by_invitation
Publish Date: April 27, 2025
Intervention Type: Drug
Study Drug: ALK-001
Study Phase: Phase 2
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
An Open-label, Phase 1/2 Trial of Gene Therapy 4D-125 in Males With X-linked Retinitis Pigmentosa (XLRP) Caused by Mutations in the RPGR Gene
Enrollment Status: Active_not_recruiting
Publish Date: March 21, 2025
Intervention Type: Biological, Other
Study Drug: 4D-125
Study Phase: Phase 1/Phase 2
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: AGTC-402
Study Phase: Phase 1/Phase 2
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene
Enrollment Status: Active_not_recruiting
Publish Date: July 22, 2022
Intervention Type: Biological
Study Drug: rAAV2tYF-PR1.7-hCNGB3
Study Phase: Phase 1/Phase 2
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
A Prospective First-In-Human Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa (adRP) Due to the P23H Mutation in the RHO Gene
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2022
Intervention Type: Drug, Other
Study Drug: QR-1123
Study Phase: Phase 1/Phase 2
Clinical and Genetic Characterization of Individuals With Achromatopsia
Clinical and Genetic Characterization of Individuals With Achromatopsia
Enrollment Status: Completed
Publish Date: October 13, 2017
View 6 Less Clinical Trials

47 Total Publications

Atypical presentation of Oguchi disease with severe cystoid macular edema and compound heterozygous SAG pathogenic variants.
Atypical presentation of Oguchi disease with severe cystoid macular edema and compound heterozygous SAG pathogenic variants.
Journal: Ophthalmic genetics
Published: October 19, 2025
Similar Doctors
Advanced in Retinopathy Pigmentary Mental Retardation
Dr. Shalesh Kaushal
Ophthalmology
Advanced in Retinopathy Pigmentary Mental Retardation
Dr. Shalesh Kaushal
Ophthalmology
3426 Nw 43rd St, Suite B, 
Gainesville, FL 
 (2.1 miles away)
352-559-1200
Languages Spoken:
English, Hindi
See accepted insurances
Accepting New Patients

Shalesh Kaushal is an Ophthalmologist in Gainesville, Florida. Dr. Kaushal is rated as an Advanced provider by MediFind in the treatment of Retinopathy Pigmentary Mental Retardation. His top areas of expertise are Late-Onset Retinal Degeneration, Age-Related Macular Degeneration (ARMD), Retinopathy Pigmentary Mental Retardation, and Retinitis Pigmentosa. Dr. Kaushal is currently accepting new patients.

Experienced in Retinopathy Pigmentary Mental Retardation
Dr. Mark B. Sherwood
Ophthalmology
Experienced in Retinopathy Pigmentary Mental Retardation
Dr. Mark B. Sherwood
Ophthalmology
1600 Sw Archer Rd, 
Gainesville, FL 
 (3.0 miles away)
352-846-2112
Languages Spoken:
English
See accepted insurances

Mark Sherwood is an Ophthalmologist in Gainesville, Florida. Dr. Sherwood is rated as an Advanced provider by MediFind in the treatment of Retinopathy Pigmentary Mental Retardation. His top areas of expertise are Glaucoma, Ocular Hypertension (OHT), Retinopathy Pigmentary Mental Retardation, Cataract, and Trabeculectomy.

Experienced in Retinopathy Pigmentary Mental Retardation
Dr. Hazem M. Samy
Ophthalmology
Experienced in Retinopathy Pigmentary Mental Retardation
Dr. Hazem M. Samy
Ophthalmology

Ocala Eye PA

4414 Sw College Rd, Unit 1462, 
Ocala, FL 
 (37.7 miles away)
352-622-5183
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Hazem Samy is an Ophthalmologist in Ocala, Florida. Dr. Samy is rated as a Distinguished provider by MediFind in the treatment of Retinopathy Pigmentary Mental Retardation. His top areas of expertise are Strabismus, Optic Neuritis, Optic Atrophy Type 1, and Optic Nerve Atrophy. Dr. Samy is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kay's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 8 Advanced Conditions
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile